MultiCell Technologies, Inc.
MultiCell Technologies, Inc.
- Market cap
- $50.01K
Your view on MCET
Overview
What the company does, where it operates, and who runs it.
About MultiCell Technologies, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- W. Gerald Newmin
- Headquarters
- 68 Cumberland Street, Woonsocket, RI, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- W. Gerald Newmin
- Headquarters
- 68 Cumberland Street, Woonsocket, RI, US
MultiCell Technologies, Inc., a biopharmaceutical company, develops novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer, and interventional cardiology and peripheral vessel applications.
Its product portfolio comprises MCT-125, a Phase II therapeutic candidate for the treatment of primary multiple sclerosis-related fatigue; MCT-465, a preclinical synthetic double-stranded RNA (dsRNA) therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers; and MCT-485, a discovery stage dsRNA therapeutic candidate with tumor cytolytic properties for the treatment of various cancers.
The company also develops Ideal BioStent, a bioabsorbable stent for interventional cardiology and peripheral vessel applications. MultiCell Technologies, Inc. has a license agreement with Corning Incorporated and Pfizer Inc. The company was formerly known as Exten Industries, Inc. and changed its name to MultiCell Technologies, Inc. in April 2004.
MultiCell Technologies, Inc. was founded in 1962 and is headquartered in Woonsocket, Rhode Island.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for MultiCell Technologies, Inc.. Starting points for MultiCell Technologies, Inc.: beta -35.68 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for MultiCell Technologies, Inc.. MultiCell Technologies, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for MultiCell Technologies, Inc.. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for MultiCell Technologies, Inc.. MultiCell Technologies, Inc. has reported as a listed company since 2000. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | Mkt cap |
|---|---|---|---|---|---|
| HESGHealth Sciences Group, Inc. | Healthcare | Biotechnology | $187,094 | ||
| LLBOLifeline Biotechnologies, Inc. | Healthcare | Medical - Specialties | $1.7M | ||
| NPHCNutra Pharma Corp. | Healthcare | Drug Manufacturers - Specialty & Generic | $709,973 | ||
| PSYBFPsyBio Therapeutics Corp. | Healthcare | Biotechnology | $1,275 | ||
| RGBPRegen BioPharma, Inc. | Healthcare | Biotechnology | $37,866 | ||
| ZIVOZIVO Bioscience, Inc. | Healthcare | Biotechnology | $36.4M | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| FBIOPFortress Biotech, Inc. | Healthcare | NASDAQ | $56.0M | ||
| FBLGFibroBiologics, Inc. Common Stock | Healthcare | NASDAQ | $6.3M | ||
| FDMT4D Molecular Therapeutics, Inc. | Healthcare | NASDAQ | $576.8M | ||
| FENCFennec Pharmaceuticals Inc. | Healthcare | NASDAQ | $462.1M | ||
| FGHQFFrontage Holdings Corporation | Healthcare | OTC | $283.9M | ||
| FHTXFoghorn Therapeutics Inc. | Healthcare | NASDAQ | $103.1M | ||
| FLNAFilana Therapeutics, Inc. | Healthcare | NASDAQ | $31.0M | ||
| FNAMEvolutionary Genomics, Inc. | Healthcare | OTC | $1,331 | ||
| FNCHQFinch Therapeutics Group, Inc. | Healthcare | OTC | — | ||
| FORUForU Holdings, Inc. | Healthcare | OTC | $2,171 | ||
| FPMIFluoroPharma Medical, Inc. | Healthcare | OTC | $6,852 | ||
| FRNMFreenome, Inc. Common stock | Healthcare | NASDAQ | $76.4M | ||
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by MultiCell Technologies, Inc. executives and directors. Shares of MultiCell Technologies, Inc. have traded between $0.0000 and $0.0000 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of MultiCell Technologies, Inc.